Catherine Bornbaum, PhD, MBA

Womens Equity Lab’s (WEL) is a fun, collaborative and empowering way for women to actively engage in early-stage investing. Launched in 2017, we now make up a diverse and powerful network of 400+ women investors, with syndicates located in Victoria, Vancouver, Toronto, Manitoba, the Atlantic and Silicon Valley. Actively engaging women in the angel investment process translates into more women as advisors, board members, venture capitalists, angel investors and angel fund managers. In the WEL model, partners in the investment round meet regularly to learn how to invest in companies, discuss opportunities, vet deal flow and make investment decisions. Every participant ends up with a deeper understanding of the angel investment process, a portfolio of early-stage companies and a great network of accomplished women. Other benefits include: • Engaging with incredible entrepreneurs and investors • Building value for the community and society • Supporting companies that resonate with you and helping them grow • Participating in new fields, transforming industries and the latest innovations • Potentially making significant financial gains • Continuous learning while building value

Sciteline is a digital health start-up whose goal is to drive an industry shift towards virtual clinical trials. Our software platform focuses on patients; collecting real-time data to improve clinical research and reimagine the patient experience.     Our tailor made platform for clinical trials can do a lot: registration and enrolment, electronic consent, patient monitoring, remote clinical assessments, notifications, telemedicine, e-diaries and access to trial data in real time. But this, and everything we do, starts with the people behind it.   Our cloud-based platform is PIPEDA and HIPPA compliant, as well as 21 CFR Part 11 certified. We know the importance of privacy and security of sensitive data.

Womens Equity Lab’s (WEL) is a fun, collaborative and empowering way for women to actively engage in early-stage investing. Launched in 2017, we now make up a diverse and powerful network of 400+ women investors, with syndicates located in Victoria, Vancouver, Toronto, Manitoba, the Atlantic and Silicon Valley. Actively engaging women in the angel investment process translates into more women as advisors, board members, venture capitalists, angel investors and angel fund managers. In the WEL model, partners in the investment round meet regularly to learn how to invest in companies, discuss opportunities, vet deal flow and make investment decisions. Every participant ends up with a deeper understanding of the angel investment process, a portfolio of early-stage companies and a great network of accomplished women. Other benefits include: • Engaging with incredible entrepreneurs and investors • Building value for the community and society • Supporting companies that resonate with you and helping them grow • Participating in new fields, transforming industries and the latest innovations • Potentially making significant financial gains • Continuous learning while building value

Sciteline is a digital health start-up whose goal is to drive an industry shift towards virtual clinical trials. Our software platform focuses on patients; collecting real-time data to improve clinical research and reimagine the patient experience.     Our tailor made platform for clinical trials can do a lot: registration and enrolment, electronic consent, patient monitoring, remote clinical assessments, notifications, telemedicine, e-diaries and access to trial data in real time. But this, and everything we do, starts with the people behind it.   Our cloud-based platform is PIPEDA and HIPPA compliant, as well as 21 CFR Part 11 certified. We know the importance of privacy and security of sensitive data.

RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpecs proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimers disease. RetiSpec is involved in multiple Alzheimers and brain health studies in leading hospitals and research networks throughout North America. RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimers disease and other causes of cognitive decline. RetiSpec was recently selected from more than 75 global applicants to receive the Davos Alzheimers Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.

Founded in 1827, the University of Toronto is Canada’s top university with a long history of challenging the impossible and transforming society through the ingenuity and resolve of our faculty, students, alumni, and supporters. We are proud to be one of the world’s top research-intensive universities, bringing together top minds from every conceivable background and discipline to collaborate on the world’s most pressing challenges. As a catalyst for discovery, innovation, and progress, we prepare our students for success through an outstanding global education and commitment to inclusive excellence. The ideas, innovations, and actions of more than 660,000 graduates advance U of T’s impact on communities across the globe.

With over 30,000 students and 300,000 alumni, Western is a leading research-intensive university and global community of individuals focused on making change in the world, today. We welcome scholars from around the world to beautiful London, Ontario.